HIDEKI GARREN, MD
Neurology at Pasteur Dr, Palo Alto, CA
License number
California G79974
Category
Neurology
Type
Neurology
Address
Address
300 Pasteur Dr, Palo Alto, CA 94305
Phone
(650) 498-5710
Professional information
Dr. Hideki Garren, Stanford CA - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
300 Pasteur Dr, Stanford 94305
(650) 498-5710 (Phone)
(650) 498-5710 (Phone)
Certifications:
Neurology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
300 Pasteur Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
University of California At Los Angeles
Graduated: 1993
Stanford University Hospital
University of California At Los Angeles
Graduated: 1993
Stanford University Hospital
Compositions And Methods For Treatment Of Autoimmune Disease
US Patent:
2010016, Jun 24, 2010
Filed:
Oct 4, 2006
Appl. No.:
12/089190
Inventors:
Nanette Solvason - Palo Alto CA, US
Michael Leviten - Palo Alto CA, US
Hideki Garren - Palo Alto CA, US
Michael Leviten - Palo Alto CA, US
Hideki Garren - Palo Alto CA, US
Assignee:
Bayhill Therapeutics, Inc - Palo Alto CA
International Classification:
A61K 31/7088, A61P 37/02, C12N 15/63
US Classification:
514 44 R, 4353201
Abstract:
Disclosed are improved methods for the treatment or prevention of an autoimmune disease comprising administration of a modified self-vector encoding and capable of expressing a self-polypeptide that includes one or more pathogenic epitopes associated with the autoimmune disease. The improved method of the present invention includes the administration to a subject of a modified self-vector or self-vectors comprising a polynucleotide encoding a self-polypeptide. In one aspect, the method includes a modified self-vector that allows for increased expression of the self-polypeptide associated with an autoimmune disease in a host cell relative to the unmodified vector. In another, non-mutually exclusive aspect, the method includes a modified self-vector that allows for a secreted autoantigen associated with an autoimmune disease to be encoded as a non-secreted self-polypeptide.
Treatment Of Demyelinating Autoimmune Disease With Modified Ordered Peptides
US Patent:
7585843, Sep 8, 2009
Filed:
Oct 1, 2004
Appl. No.:
10/589067
Inventors:
Hideki Garren - Palo Alto CA, US
Stephanie Broome - Palo Alto CA, US
Stephanie Broome - Palo Alto CA, US
Assignee:
Bayhill Therapeutics, Inc. - San Mateo CA
International Classification:
A61K 38/10
US Classification:
514 14
Abstract:
Compositions and methods are provided for the treatment or prevention of autoimmune disease. Therapeutic doses of one or more modified therapeutic ordered peptide(s) comprising amino acids representing a consensus sequence of a protein identified as a target of the autoimmune T and B cell response are described. Of particular interest are therapeutic ordered peptides of the autoantigens in multiple sclerosis, for example the myelin proteins MBP, MOG, PLP, MAG and cyclic nucleotide phosphodiesterase. The therapeutic ordered peptide may be extended at either termini by the addition of other D- or L- amino acid residues. The therapeutic ordered peptides may be administered topically or parenterally, by injection at a particular site, including subcutaneously, intraperitoneally, intravascularly, or the like or transdermally, as by electrotransport. The compositions of the invention may also contain other therapeutically active agents.
Polynucleotide Therapy
US Patent:
2009026, Oct 22, 2009
Filed:
May 18, 2009
Appl. No.:
12/467866
Inventors:
Paulo Fontoura - Mountain View CA, US
Hideki Garren - Palo Alto CA, US
William H. Robinson - Menlo Park CA, US
Lawrence Steinman - Stanford CA, US
Pedro Jose Ruiz - Redwood City CA, US
Paul J. Utz - Portola Valley CA, US
Hideki Garren - Palo Alto CA, US
William H. Robinson - Menlo Park CA, US
Lawrence Steinman - Stanford CA, US
Pedro Jose Ruiz - Redwood City CA, US
Paul J. Utz - Portola Valley CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
Bayhill Therapeutics/Stanford - San Mateo CA
Bayhill Therapeutics/Stanford - San Mateo CA
International Classification:
A61K 31/7088, A61P 21/00
US Classification:
514 44 R
Abstract:
This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of a non-physiologic process in the animal.
Therapeutic And Diagnostic Uses Of Antibody Specificity Profiles
US Patent:
7785819, Aug 31, 2010
Filed:
Apr 10, 2002
Appl. No.:
10/120578
Inventors:
William H. Robinson - Menlo Park CA, US
David L. Hirschberg - Menlo Park CA, US
Lawrence Steinman - Palo Alto CA, US
Pedro Jose Ruiz - Redwood City CA, US
Paul J. Utz - Stanford CA, US
Hideki Garren - Stanford CA, US
David L. Hirschberg - Menlo Park CA, US
Lawrence Steinman - Palo Alto CA, US
Pedro Jose Ruiz - Redwood City CA, US
Paul J. Utz - Stanford CA, US
Hideki Garren - Stanford CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CO
International Classification:
G01N 33/00
US Classification:
435 792
Abstract:
This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.
Therapeutic And Diagnostic Uses Of Antibody Specificity Profiles
US Patent:
2010033, Dec 30, 2010
Filed:
Aug 30, 2010
Appl. No.:
12/871765
Inventors:
William H. Robinson - Menlo Park CA, US
David L. Hirschberg - Menlo Park CA, US
Lawrence Steinman - Palo Alto CA, US
Pedro Jose Ruiz - Menlo Park CA, US
Paul J. Utz - Stanford CA, US
Hideki Garren - Palo Alto CA, US
David L. Hirschberg - Menlo Park CA, US
Lawrence Steinman - Palo Alto CA, US
Pedro Jose Ruiz - Menlo Park CA, US
Paul J. Utz - Stanford CA, US
Hideki Garren - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 39/00, C40B 30/04, C40B 40/10, A61P 3/10
US Classification:
4241841, 506 9, 506 18
Abstract:
This invention provides a method for determining the antibody specificity profile in an individual. This specificity profile reveals the individual's immune response to multiple antigens and/or epitopes of autoantigens, allergens, graft antigens, etc. The antibody specificity profile is determined through the binding of patient samples comprising antibodies to the arrays. The array can comprises antigens and epitopes. The invention also provides the means and methods for determining antigen or epitope specificity profiles that can be used in the development of either generic and individualized diagnosis and treatment for immune related diseases, including autoimmune disease, allergy and graft rejection.
Dna Vaccination For Treatment Of Autoimmune Disease
US Patent:
7704970, Apr 27, 2010
Filed:
Oct 24, 2007
Appl. No.:
11/923139
Inventors:
Lawrence Steinman - Palo Alto CA, US
Pedro Ruiz - Menlo Park CA, US
Hideki Garren - Palo Alto CA, US
Pedro Ruiz - Menlo Park CA, US
Hideki Garren - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A01N 43/04, C12N 15/00, A61K 31/70
US Classification:
514 44R, 4353201
Abstract:
A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.
Dna Vaccination For Treatment Of Multiple Sclerosis And Insulin-Dependent Diabetes Mellitus
US Patent:
2011003, Feb 10, 2011
Filed:
Apr 5, 2010
Appl. No.:
12/754555
Inventors:
LAWRENCE STEINMAN - PALO ALTO CA, US
PEDRO RUIZ - MENLO PARK CA, US
HIDEKI GARREN - PALO ALTO CA, US
PEDRO RUIZ - MENLO PARK CA, US
HIDEKI GARREN - PALO ALTO CA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY - PALO ALTO CA
International Classification:
A61K 31/7088, A61P 19/00, A61P 37/00
US Classification:
514 44 R
Abstract:
A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.
Dna Vaccination For Treatment Of Multiple Sclerosis And Insulin-Dependent Diabetes Mellitus
US Patent:
7579328, Aug 25, 2009
Filed:
Nov 28, 2005
Appl. No.:
11/289226
Inventors:
Lawrence Steinman - Palo Alto CA, US
Pedro Ruiz - Menlo Park CA, US
Hideki Garren - Palo Alto CA, US
Pedro Ruiz - Menlo Park CA, US
Hideki Garren - Palo Alto CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A01N 43/04, C12N 15/00
US Classification:
514 44, 4353201
Abstract:
A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive T cells and the secretion of Th1 cytokines, including IL-2, IFN-γ and IL-15, are reduced.
Use Of Statins And Other Immunomodulatory Agents In The Treatment Of Autoimmune Disease
US Patent:
2003022, Dec 11, 2003
Filed:
Mar 31, 2003
Appl. No.:
10/404679
Inventors:
Lawrence Steinman - Stanford CA, US
Hideki Garren - Palo Alto CA, US
Hideki Garren - Palo Alto CA, US
International Classification:
A61K048/00, A61K038/16, A61K031/401, A61K031/366
US Classification:
514/044000, 514/423000, 514/460000, 514/002000
Abstract:
Methods are provided for the treatment of autoimmune diseases, by co-administering a statin and a second immunomodulaotry agent. The second immunomodulatory agent can be antigen-specific or non-antigen-specific.